Vera Therapeutics, Inc. (VERA) News

Vera Therapeutics, Inc. (VERA): $17.19

1.36 (+8.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VERA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 389

in industry

Filter VERA News Items

VERA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VERA News Highlights

  • For VERA, its 30 day story count is now at 6.
  • Over the past 15 days, the trend for VERA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.

Latest VERA News From Around the Web

Below are the latest news stories about Vera Therapeutics Inc that investors may wish to consider to help them evaluate VERA as an investment opportunity.

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 22, 2022

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters’ option to purchase up to 748,959 additional shares. The gross

Yahoo | February 14, 2022

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its public offering of 4,993,067 shares of its Class A common stock at a price to the public of $15.00 per share. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commiss

Yahoo | February 10, 2022

Vera Therapeutics announces public offering of 4M class A shares

Vera Therapeutics (NASDAQ:VERA) commenced a public offering to issue and sell 4M class A shares. VERA expects to grant the underwriters a 30-day option to purchase up to an additional 600K class A shares....

Seeking Alpha | February 7, 2022

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering, subject to market and other conditions, to issue and sell 4,000,000 shares of its Class A common stock. All of the shares are being offered by Vera. In connection with the proposed offering, Vera expects

Yahoo | February 7, 2022

Vera Therapeutics plans phase 3 study of atacicept to treat lupus nephritis

Vera Therapeutics <> plans to begin a phase 3 trial of its lead product candidate atacicept in lupus nephritis ((LN)). The company said it received positive feedback from the U.S

Seeking Alpha | January 18, 2022

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical trial of its lead product candidate atacicept in lupus nephritis (LN). This announcement comes after positive feedback

Yahoo | January 18, 2022

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

No summary available.

Seeking Alpha | January 7, 2022

Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder and CEO, will present and participate in one-on-one investor meetings at the 40th Annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022. Presentation details: Date:Januar

Yahoo | January 4, 2022

Evercore ISI Sticks to Their Buy Rating for Vera Therapeutics (VERA)

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $30.00. The company's shares closed last Monday at $20.27. According to TipRanks.com, Bayko is a 4-star analyst with an average return of 10.0% and a 43.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals. Currently, the analyst consensus on Vera Therapeutics is a Moderate Buy with an average price target of $30.00. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $37.11 and a one-year low of $11.30.

Brian Anderson on TipRanks | December 21, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6175 seconds.